SE8803472A - - Google Patents

Info

Publication number
SE8803472A
SE8803472A SE8803472A SE8803472A SE8803472A SE 8803472 A SE8803472 A SE 8803472A SE 8803472 A SE8803472 A SE 8803472A SE 8803472 A SE8803472 A SE 8803472A SE 8803472 A SE8803472 A SE 8803472A
Authority
SE
Sweden
Prior art keywords
treatment
interferon
gamma
relates
present
Prior art date
Application number
SE8803472A
Other languages
English (en)
Other versions
SE462364B (sv
SE8803472D0 (sv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to SE8803472A priority Critical patent/SE462364B/sv
Publication of SE8803472D0 publication Critical patent/SE8803472D0/sv
Publication of SE8803472A publication Critical patent/SE8803472A/xx
Priority to PCT/SE1989/000520 priority patent/WO1990003189A1/en
Priority to JP1510051A priority patent/JP2895896B2/ja
Priority to US07/671,786 priority patent/US5208019A/en
Priority to DE89850317T priority patent/DE68905438T2/de
Priority to AT89850317T priority patent/ATE86869T1/de
Priority to IL9179689A priority patent/IL91796A/en
Priority to EP89850317A priority patent/EP0367735B1/en
Priority to AU43051/89A priority patent/AU623181B2/en
Priority to HU895542A priority patent/HU206988B/hu
Priority to KR1019900701144A priority patent/KR0137017B1/ko
Priority to NZ230816A priority patent/NZ230816A/en
Priority to DD89333072A priority patent/DD288094A5/de
Priority to PT91863A priority patent/PT91863B/pt
Priority to IE312389A priority patent/IE63874B1/en
Priority to PH39308A priority patent/PH26293A/en
Priority to CA000614859A priority patent/CA1338722C/en
Publication of SE462364B publication Critical patent/SE462364B/sv
Priority to DK199100562A priority patent/DK174523B1/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SE8803472A 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos SE462364B (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
HU895542A HU206988B (en) 1988-09-30 1989-09-27 Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient
JP1510051A JP2895896B2 (ja) 1988-09-30 1989-09-27 脈管狭窄の治療におけるγ―インターフェロンの使用
EP89850317A EP0367735B1 (en) 1988-09-30 1989-09-27 Use of gamma interferon in pharmaceutical preparations for the treatment of vascular stenosis
KR1019900701144A KR0137017B1 (ko) 1988-09-30 1989-09-27 감마-인터페론을 이용한 혈관 협착증의 치료방법
US07/671,786 US5208019A (en) 1988-09-30 1989-09-27 Use of gamma-interferon for the treatment of vascular stenosis
DE89850317T DE68905438T2 (de) 1988-09-30 1989-09-27 Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose.
AT89850317T ATE86869T1 (de) 1988-09-30 1989-09-27 Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.
IL9179689A IL91796A (en) 1988-09-30 1989-09-27 Pharmacological preparations containing gamma interferon
PCT/SE1989/000520 WO1990003189A1 (en) 1988-09-30 1989-09-27 Use of gamma-interferon for the treatment of vascular stenosis
AU43051/89A AU623181B2 (en) 1988-09-30 1989-09-27 Use of gamma-interferon for the treatment of vascular stenosis
DD89333072A DD288094A5 (de) 1988-09-30 1989-09-28 Verwendung von gamma-interferon zur behandlung von gefaessverengungen
NZ230816A NZ230816A (en) 1988-09-30 1989-09-28 Gamma interferon, treatment of vascular stenosis
CA000614859A CA1338722C (en) 1988-09-30 1989-09-29 Gamma-interferon for the treatment of vascular stenosis
PT91863A PT91863B (pt) 1988-09-30 1989-09-29 Processo de preparacao de uma preparacao farmaceutica a base de gama-interferao
IE312389A IE63874B1 (en) 1988-09-30 1989-09-29 Use of gamma-interferon for the treatment of vascular stenosis
PH39308A PH26293A (en) 1988-09-30 1989-09-29 Use of gamma-interferon for the treatment of vascular stenosis
DK199100562A DK174523B1 (da) 1988-09-30 1991-03-27 Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos

Publications (3)

Publication Number Publication Date
SE8803472A true SE8803472A (sv) 1988-09-30
SE8803472D0 SE8803472D0 (sv) 1988-09-30
SE462364B SE462364B (sv) 1990-06-18

Family

ID=20373494

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos

Country Status (18)

Country Link
US (1) US5208019A (sv)
EP (1) EP0367735B1 (sv)
JP (1) JP2895896B2 (sv)
KR (1) KR0137017B1 (sv)
AT (1) ATE86869T1 (sv)
AU (1) AU623181B2 (sv)
CA (1) CA1338722C (sv)
DD (1) DD288094A5 (sv)
DE (1) DE68905438T2 (sv)
DK (1) DK174523B1 (sv)
HU (1) HU206988B (sv)
IE (1) IE63874B1 (sv)
IL (1) IL91796A (sv)
NZ (1) NZ230816A (sv)
PH (1) PH26293A (sv)
PT (1) PT91863B (sv)
SE (1) SE462364B (sv)
WO (1) WO1990003189A1 (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2131550A1 (en) * 1992-02-05 1993-08-19 Andrew Zalewski Interferon gene therapy for the treatment of vascular disorders
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
HU220969B1 (hu) * 1993-01-07 2002-07-29 Thomas Jefferson University A C-MYC-re specifikus antiszensz oligonukleotid alkalmazása simaizomsejtek proliferációjának szabályozásában
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
EP0797998A4 (en) * 1995-11-17 2003-01-15 Toray Industries PROTECTION FOR ENDOTHEL CELLS
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
ES2314786T3 (es) 1998-04-02 2009-03-16 Genentech, Inc. Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca.
US7524826B2 (en) * 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3261761D1 (en) * 1981-07-14 1985-02-14 Efamol Ltd Pharmaceutical and dietary composition when used for enhancement of 1-series pg production
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4454115A (en) * 1981-10-23 1984-06-12 Wisconsin Alumni Research Foundation Method of reducing the level of low density lipoproteins in the serum of a patient
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
HUT57063A (en) 1991-11-28
ATE86869T1 (de) 1993-04-15
IL91796A (en) 1994-10-07
IL91796A0 (en) 1990-06-10
PH26293A (en) 1992-04-10
EP0367735B1 (en) 1993-03-17
JP2895896B2 (ja) 1999-05-24
DE68905438D1 (de) 1993-04-22
SE462364B (sv) 1990-06-18
DD288094A5 (de) 1991-03-21
PT91863B (pt) 1995-05-31
DE68905438T2 (de) 1993-09-30
SE8803472D0 (sv) 1988-09-30
DK56291D0 (da) 1991-03-27
NZ230816A (en) 1997-06-24
AU623181B2 (en) 1992-05-07
JPH04500966A (ja) 1992-02-20
DK56291A (da) 1991-05-24
US5208019A (en) 1993-05-04
HU895542D0 (en) 1991-10-28
WO1990003189A1 (en) 1990-04-05
CA1338722C (en) 1996-11-19
AU4305189A (en) 1990-04-18
DK174523B1 (da) 2003-05-12
KR0137017B1 (ko) 1998-04-25
EP0367735A1 (en) 1990-05-09
PT91863A (pt) 1990-03-30
IE893123L (en) 1990-03-30
KR900701308A (ko) 1990-12-01
IE63874B1 (en) 1995-06-14
HU206988B (en) 1993-03-01

Similar Documents

Publication Publication Date Title
SE8803472A (sv)
WO1988006026A3 (en) Internal prosthesis for the substitution of a part of the human body particularly in vascular surgery
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
ATE186460T1 (de) Methode zur verhinderung von restenosierung nach rekanalisierung von körpergefässen
HUT64231A (en) Process for the production of medical preparatives containing heparing and rapamycin for the preventing and treatment of blood-vessel diseases caused by hyper proliferation
EP0376251A3 (en) An anticoagulant substance obtained from urine
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
NO924066D0 (no) Terapeutisk middel
HU911756D0 (en) Process for the production of medical preparations containing magnesium-pyridoxal-5'-phosphate-glutaminate, for the preventing of arterial diseases
AU6178094A (en) Polyurethane-coated intravascular prostheses (stents) for the treatment of blood vessel stenosis
NO308856B1 (no) Dermatansulfater og salter av disse
DK0590321T3 (da) Anvendelse af NADH og NADPH til fremstilling af et lægemiddel til behandling af Alzheimers sygdom
EP1222854A4 (en) PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH BLOOD COAGULATION
ATE164521T1 (de) Anti-wachstumsfaktor antikörper in der behandlung von gefässstenose
TW223589B (sv)
ID23176A (id) Metoda untuk mengobati gangguan pembuluh darah
UA37249C2 (uk) Спосіб інгібування стенозу та/або рестенозу (варіанти), спосіб інгібування рестенозу після проведення операції на коронарній артерії у людини (варіанти), спосіб зниження ймовірності виникнення чи запобігання негострих ішемічних ускладнень при ангіопластиці у людини
HU9200025D0 (en) Medical preparations for treating depression
DE68906437D1 (de) L-pyroglutamyl-l-cystein-dipeptid mit hoher anti-cataractogener wirkung und dies enthaltende pharmazeutische zusammensetzungen.
DK417889D0 (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
EP0282844A3 (en) Use of dopamine-agonists in the preparation of a medicament for the treatment of bone injuries
ITVR930047V0 (it) Letto per la terapia di fluidizzazione in particolare per il decupito o la cura di ustioni
DK1889D0 (da) Kombineret behandling af arteria femoralis superficialis okklusion med perkutan transluminal angioplastik og lokalt indelukket rekombineret plasminogen aktivator. 4 lumen dobbelt ballon kateter

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8803472-3

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8803472-3

Format of ref document f/p: F